Effects of metabolic approach in diabetic patients with coronary artery disease

Current Pharmaceutical Design

Volumn 15, Issue 8, 2009, Pages 857-862

  Fragasso, Gabriele ^a   Salerno, Anna ^a   Spoladore, Roberto ^a   Cera, Michela ^a   Montanaro, Claudia ^a   Margonato, Alberto ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A ACYLTRANSFERASE; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARNITINE PALMITOYLTRANSFERASE I; ENDOTHELIN 1; ETOMOXIR; FATTY ACID; MOXONIDINE; OXFENICINE; PERHEXILINE; TRIMETAZIDINE;

ACUTE DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE COURSE; DRUG FATALITY; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; ENZYME INHIBITION; FATTY ACID BLOOD LEVEL; FATTY ACID OXIDATION; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLUCOSE OXIDATION; GLUCOSE TRANSPORT; GLYCOLYSIS; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HEART MUSCLE OXYGEN CONSUMPTION; HUMAN; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIVER TOXICITY; METABOLIC REGULATION; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; STABLE ANGINA PECTORIS;

ACETYL-COA C-ACYLTRANSFERASE; CARNITINE O-PALMITOYLTRANSFERASE; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; FATTY ACIDS, NONESTERIFIED; GLUCOSE; HUMANS; TRIMETAZIDINE; VASODILATOR AGENTS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 65649099707     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209787582093     Document Type: Review

References (59)

1. Piatti PM, Monti LD, Galli L, Fragasso G, Valsecchi G, Conti M, et al. Relationship between endothelin-1 concentrations and the metabolic alterations typical of the insulin resistance syndrome. Metabolism 2000; 49: 748-52.
2. Piatti PM, Monti LD, Zavaroni I, Valsecchi G, Van Phan C, Costa S, et al. Alterations in nitric oxide/cyclic-GMP pathway in nondiabetic siblings of patients with type 2 diabetes. J Clin Endocrinol Metab 2000; 85: 2416-20.
3. Yokoyama I, Yonekura K, Ohtake T, Kawamura H, Matsumoto A, Inoue Y, et al. Role of insulin resistance in heart and skeletal muscle F-18 fluorodeoxyglucose uptake in patients with non-insulin-dependent diabetes mellitus. J Nucl Cardiol 2000; 7: 242-8.
4. Natali A, Taddei S, Quiñones Galvan A, Camastra S, Baldi S, Frascerra S, et al. Insulin sensitivity, vascular reactivity, and clamp-induced vasodilatation in essential hypertension. Circulation 1997; 96: 725-6.
5. Despres JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952-7.
6. Yoshimura T, Hisatomi A, Kajihara S, Yasutake T, Ogawa Y, Mizuta T, et al. The Relationship between insulin resistance and polymorphisms of the endothelial nitric oxide synthase gene in patients with coronary artery disease. J Atheroscler Thromb 2003; 10: 43-7.
7. Piatti PM, Fragasso G, Monti LD, Caumo A, Phan VC, Valsecchi G, et al. Endothelial and metabolic characteristics of patients with angina and angiographically normal coronary arteries. J Am Coll Cardiol 1999; 34: 1452-60.
8. Paolisso G, De Riu S, Marrazzo G, Verza M, Varricchio M, D'Onofrio F. Insulin resistance and hyperinsulinemia in patients with chronic heart failure. Metabolism 1991; 40: 972-7.
9. Piatti P, Di Mario C, Monti LD, Fragasso G, Sgura F, Caumo A, et al. Association of insulin resistance, hyperleptinemia, and impaired nitric oxide release with in-stent restenosis in patients undergoing coronary stenting. Circulation 2003; 108: 2074-81.
10. The Decode Study Group. Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999; 354: 617-21
11. Nuutila P, Knuuti MJ, Raitakari M, Ruotsalainen U, Teras M, Voipio-Pulkki LM, et al. Effect of antilipolysis on heart and skeletal muscle glucose uptake in overnight fasted humans. Am J Physiol 1994; 267: E941-6.
12. Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 2002; 23: 201-29.
13. Steinberg HO, Baron AD. Vascular function, insulin resistance and fatty acids. Diabetologia 2002; 45: 623-34.
14. Piro S, Spampinato D, Spadaro L, Oliveri CE, Purrello F, Rabuazzo AM. Direct apoptotic effects of free fatty acids on human endothelial cells. Nutr Metab Cardiovasc Dis. 2008; 18: 96-104.
15. Abdul-Ghani MA, Muller FL, Liu Y, Chavez AO, Balas B, Zuo P, et al. Deleterious action of FA metabolites on ATP synthesis: Possible link between lipotoxicity, mitochondrial dysfunction, and insulin resistance. Am J Physiol Endocrinol Metab. 2008; 295: E678-85.
16. Wallhaus TR, Taylor M, DeGrado TR, Russell DC. Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure. Circulation 2001; 103: 2441-6.
17. Podbregar M, Voga G. Effect of selective and nonselective beta-blockers on resting energy production rate and total body substrate utilization in chronic heart failure. J Cardiac Fail 2002: 8: 369-378.
18. Sharma V, Dhillon P, Wambolt R, Parsons H, Brownsey R, Allard MF, et al. Metoprolol improves cardiac function and modulates cardiac metabolism in the streptozotocin (STZ) diabetic rat. Am J Physiol Heart Circ Physiol 2008; 294: H1609-20.
19. Poole-Wilson P, Swedberg K, Cleland J, Di Lenarda A, Hanrath P, Komajda M, et al. Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): Randomised controlled trial. Lancet 2003; 362: 7-13.
20. Wiltse C, Wright T; for the MOXCON Investigators. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 2003; 5: 659-66
21. Mobini R, Jansson PA, Bergh CH, Sharing Tang M, Waagstein F, Andersson B. Influence of central inhibition of sympathetic nervous activity on myocardial metabolism in chronic heart failure: Acute effects of the imidazoline I1-receptor agonist moxonidine. Clin Sci 2006; 110: 329-36.
22. Fragasso G, Salerno A, Margonato A. Heart rate reduction is probably not the main beneficial mechanism by which beta blockade improves outcome in patients with systolic chronic heart failure. Am J Cardiol 2008; 102: 506-7.
23. Chierchia S, Fragasso G: Metabolic management of ischaemic heart disease. Eur Heart J 1993; 14(Suppl G): 2-5.
24. Fragasso G, De Cobelli F, Perseghin G, Esposito A, Palloshi A, Bassanelli G, et al. Improved myocardial high-energy phosphate metabolism induced by partial fatty acid inhibition in patients with heart failure. J Am Coll Cardiol 2004; 43: 190A.
25. Monti LD, Allibardi S, Piatti PM, Valsecchi G, Costa S, Pozza G, et al. Triglycerides impair postischemic recovery in isolated hearts: roles of endothelin-1 and trimetazidine. Am J Physiol Heart Circ Physiol 2001; 281: H1122-30.
26. Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial longchain 3-ketoacyl coenzyme A thiolase. Circ Res 2000; 86: 580-8.
27. Brottier L, Barat JL, Combe C, Boussens B, Bonnet J, Bricaud H. Therapeutic value of a cardioprotective agent in patients with severe ischemic cardiomyopathy. Eur Heart J 1990; 11: 207-12.
28. Lu C, Dabrowski P, Fragasso G, Chierchia SL. Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease. Am J Cardiol 1998; 82: 898-901
29. Fragasso G, Piatti PM, Monti L, Palloshi A, Setola E, Puccetti P, et al. Short and long term beneficial effects of partial free fatty acid inhibition in diabetic patients with ischemic dilated cardiomyopathy. Am Heart J 2003; 146: E1-8.
30. Rosano GMC, Vitale C, Sposato B, Mercuro G, Fini M. Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: A double-blind placebo-controlled study. Cardiovasc Diabetol 2003; 2: 16/1-16/9.
31. Szwed H, Pachocki R, Domnzal-Bochenska M, Szymczak K, Szydłowski Z, Paradowski A, et al. The antiischemic effects and tolerability of trimetazidine in coronary diabetic patients. A substudy from TRIMPOL-I. Cardiovasc Drugs Ther 1999; 13: 215-20.
32. Malmberg K, Ryden L, Hamsten A, Herlitz J, Waldenström A, Wedel H. Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. DIGAMI study group, Eur Heart J 1996; 17: 1337-44.
33. Diaz R, Paolasso EC, Piegas LS, Tajer CD, Moreno MG, Corvalán R, et al. Metabolic modulation of acute myocardial infarction. The ECLA glucose- insulin-potassium pilot trial. Circulation 1998; 98: 2227-34
34. Fath-Ordoubadi F, Beatt KJ. Glucose-insulin-potassium (GIK) therapy for treatment of acute myocardial infarction: An overview of randomized placebo controlled trials. Circulation 1997; 96: 1152-6
35. Fragasso G, Piatti P, Monti L, Palloshi A, Lu C, Valsecchi G, et al. Acute effects of heparin administration on the ischemic threshold of patients with coronary artery disease: Evaluation of the protective role of the metabolic modulator trimetazidine. J Am Coll Cardiol 2002; 39: 413-9.
36. Yamauchi-Kohno R, Miyauchi T, Hoshino T, Kobayashi T, Aihara H, Sakai S, et al. Role of endothelin in deterioration of heart failure due to cardiomyopathy in hamsters: Increase in endothelin production in the heart and beneficial effect of endothelin A antagonist on survival and cardiac function. Circulation 1999; 99: 2171-6.
37. Maridonneau-Parini I, Harpey C. Effects of trimetazidine on membrane damage induced by oxygen free radicals in human red cells. Br J Clin Pharmacol 1985; 20: 148-151.
38. Cano C, Bermúdez VJ, Medina MT, Bermúdez FA, Ambard MJ, Souki AJ, et al. Trimetazidine diminishes fasting glucose in rats with fasting hyperglycemia: A preliminary study. Am J Ther 2003; 10: 444-6.
39. Monti LD, Setola E, Fragasso G, Camisasca RP, Lucotti P, Galluccio E, et al. Metabolic and Endothelial Effects of Trimetazidine on Forearm Muscle in Patients with Type 2 Diabetes and Ischemic Cardiomyopathy. Am J Physiol Endocrinol Metab 2006; 290: E54-9.
40. Fragasso G, Montano C, Perseghin G, Palloshi A, Calori G, Lattuada G, et al. The antiischaemic effect of trimetazidine in patients with postprandial myocardial ischemia is unrelated to meal composition. Am Heart J 2006; 151: 1238.e1-1238.e8.
41. Lopashuck GD, Wall SR, Olley PM, Davies NJ. Etomoxir, a carnitine palmitoyltransferase I inhibitor, protects hearts from fatty acid-induced ischemic injury independent of changes in long chain acylcarnitine. Circ Res 1988; 63: 1036-43.
42. Ratheiser K, Schneeweiss B, Waldhausl W, Fasching P, Korn A, Nowotny P, et al. Inhibition by etomoxir of carnitine palmitoyltransferase I reduces hepatic glucose production and plasma lipids in non-insulin-dependent diabetes mellitus. Metabolism 1991; 40: 1185-9062.
43. Turcani M, Rupp H. Etomoxir improves left ventricular performance of pressure-overloaded rat heart. Circulation 1997; 96: 3681-6
44. Zarain-Herzberg A, Rupp H. Therapeutic potential of CPT I inhibitors: cardiac gene transcription as a target. Expert Opin Investig Drugs 2002; 11: 345-56
45. Schmidt-Schweda S, Holubarsch C. First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin Sci 2000; 99: 27-35
46. Schmitz FJ, Rösen P, Reinauer H. Improvement of myocardial function and metabolism in diabetic rats by the carnitine palmitoyl transferase inhibitor etomoxir. Horm Metab Res 1995; 27: 515-22
47. Cabreros A, Merlos M, Laguna JC, Carrera MV. Down-regulation of acyl-CoA oxidase gene expression and increased NF-kappaB activity in etomoxir-induced cardiac hypertrophy. J Lipid Res 2003; 44: 388-98.
48. Merril CL, Ni H, Yoon LW, Yoon LW, Tirmenstein MA, Narayanan P, et al. Etomoxir-induced oxidative stress in HepG2 cells detected by differential gene expression is confirmed biochemically. Toxicol Sci 2002; 68: 93-101.
49. Kennedy JA, Kiosoglus AJ, Murphy GA, Pelle MA, Horowitz JD. Effect of perhexilline and oxfenicine on myocardial function and metabolism during low flow ischemia/reperfusion in the isolated rat heart. J Cardiovasc Pharmacol 2000; 36: 794-801
50. Jeffrey FM, Alvarez L, Diczku V, Sherry AD, Mallory CR. Direct evidence that perhexiline modifies myocardial substrate utilization from fatty acids to lactate. J Cardiovasc Pharmacol 1995; 25: 469-72
51. Stephens TW, Higgins AJ, Cook GA, Harris RA. Two mechanisms produce tissue-specific inhibition of fatty acid oxidation by oxfenicine. Biochem J 1985; 227: 651-60
52. Bergman G, Atkinson L, Metcalfe J, Jackson J, Jewitt DE. Beneficial effect of enhanced myocardial carbohydrate utilisation after oxfenicine (L-hydroxyphenylglycine) in angina pectoris. Eur Heart J 1980; 1: 247-53.
53. Cole PL, Beamer AD, McGowan N, Cantillon CO, Benfell K, Kelly RA, et al. Efficacy and safety of perhexiline maleate in refractory angina: a double-blind placebo-controlled clinical trial of a novel antianginal agent. Circulation 1990; 81: 1260-70.
54. Lee L, Campbell R, Scheuermann-Freestone M, Taylor R, Gunaruwan P, Williams L, et al. Metabolic modulation with perhexiline in chronic heart failure. A randomized, controlled trial of short-term use of a novel treatment. Circulation 2005; 112: 3280-8.
55. Meier C, Wahllaender A, Hess CW, Preisig R. Perhexiline-induced lipidosis in the dark Agouti (DA) rat: An animal model of genetically determined neurotoxicity. Brain 1986; 109: 649-660.
56. Killalea SM, Krum H. Systematic review of the efficacy and safety of perhexiline in the treatment of ischemic heart disease. Am J Cardiovasc Drugs 2001; 1: 193-204.
57. Chen L, Rogers SL, Colagiuri S, Cadilhac DA, Mathew TH, Boyden AN, et al. How do the Australian guidelines for lipid-lowering drugs perform in practice? Cardiovascular disease risk in the Aus-Diab Study 1999-2000. Med J Aust 2008; 189(6): 319-322.
58. Goodman CD, McFadden GI. Fatty acid synthesis in protozoan parasites: unusual pathways and novel drug targets. Curr Pharm Des 2008; 14(9): 901-16.
59. Jandeleit-Dahm K, Cooper ME. The role of AGEs in cardiovascular disease. Curr Pharm Des 2008; 14(10): 979-86.